Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Capital Leases (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Capital Leases for 5 consecutive years, with $122000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Leases fell 35.11% year-over-year to $122000.0, compared with a TTM value of $122000.0 through Sep 2025, down 35.11%, and an annual FY2024 reading of $122000.0, down 47.19% over the prior year.
  • Capital Leases was $122000.0 for Q3 2025 at Aligos Therapeutics, roughly flat from $122000.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $261000.0 in Q4 2021 and bottomed at $53000.0 in Q3 2021.
  • Average Capital Leases over 5 years is $175421.1, with a median of $188000.0 recorded in 2023.
  • The sharpest move saw Capital Leases skyrocketed 228.3% in 2022, then plummeted 47.19% in 2024.
  • Year by year, Capital Leases stood at $261000.0 in 2021, then dropped by 11.88% to $230000.0 in 2022, then increased by 0.43% to $231000.0 in 2023, then tumbled by 47.19% to $122000.0 in 2024, then changed by 0.0% to $122000.0 in 2025.
  • Business Quant data shows Capital Leases for ALGS at $122000.0 in Q3 2025, $122000.0 in Q2 2025, and $122000.0 in Q1 2025.